Literature DB >> 29367691

Osteoporosis: Romosozumab to rebuild the foundations of bone strength.

Serge L Ferrari1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 29367691     DOI： 10.1038/nrrheum.2018.5

Source DB:  PubMed          Journal:  Nat Rev Rheumatol        ISSN： 1759-4790            Impact factor:   20.543


× No keyword cloud information.
  10 in total

Review 1.  Sclerostin and Dickkopf-1 as therapeutic targets in bone diseases.

Authors:  Hua Zhu Ke; William G Richards; Xiaodong Li; Michael S Ominsky
Journal:  Endocr Rev       Date:  2012-06-20       Impact factor: 19.871

2.  Romosozumab Treatment in Postmenopausal Osteoporosis.

Authors:  Felicia Cosman; Daria B Crittenden; Andreas Grauer
Journal:  N Engl J Med       Date:  2017-01-26       Impact factor: 91.245

3.  Romosozumab (sclerostin monoclonal antibody) versus teriparatide in postmenopausal women with osteoporosis transitioning from oral bisphosphonate therapy: a randomised, open-label, phase 3 trial.

Authors:  Bente L Langdahl; Cesar Libanati; Daria B Crittenden; Michael A Bolognese; Jacques P Brown; Nadia S Daizadeh; Eva Dokoupilova; Klaus Engelke; Joel S Finkelstein; Harry K Genant; Stefan Goemaere; Lars Hyldstrup; Esteban Jodar-Gimeno; Tony M Keaveny; David Kendler; Peter Lakatos; Judy Maddox; Jorge Malouf; Fabio E Massari; Jose Fernando Molina; Maria Rosa Ulla; Andreas Grauer
Journal:  Lancet       Date:  2017-07-26       Impact factor: 79.321

4.  Sustained Modeling-Based Bone Formation During Adulthood in Cynomolgus Monkeys May Contribute to Continuous BMD Gains With Denosumab.

Authors:  Michael S Ominsky; Cesar Libanati; Qing-Tian Niu; Rogely W Boyce; Paul J Kostenuik; Rachel B Wagman; Roland Baron; David W Dempster
Journal:  J Bone Miner Res       Date:  2015-07       Impact factor: 6.741

5.  Romosozumab in postmenopausal women with low bone mineral density.

Authors:  Michael R McClung; Andreas Grauer; Steven Boonen; Michael A Bolognese; Jacques P Brown; Adolfo Diez-Perez; Bente L Langdahl; Jean-Yves Reginster; Jose R Zanchetta; Scott M Wasserman; Leonid Katz; Judy Maddox; Yu-Ching Yang; Cesar Libanati; Henry G Bone
Journal:  N Engl J Med       Date:  2014-01-01       Impact factor: 91.245

6.  Effect of Abaloparatide vs Placebo on New Vertebral Fractures in Postmenopausal Women With Osteoporosis: A Randomized Clinical Trial.

Authors:  Paul D Miller; Gary Hattersley; Bente Juel Riis; Gregory C Williams; Edith Lau; Luis Augusto Russo; Peter Alexandersen; Cristiano A F Zerbini; Ming-yi Hu; Alan G Harris; Lorraine A Fitzpatrick; Felicia Cosman; Claus Christiansen
Journal:  JAMA       Date:  2016-08-16       Impact factor: 56.272

Review 7.  Denosumab and bisphosphonates: different mechanisms of action and effects.

Authors:  Roland Baron; Serge Ferrari; R Graham G Russell
Journal:  Bone       Date:  2010-12-09       Impact factor: 4.398

8.  10 years of denosumab treatment in postmenopausal women with osteoporosis: results from the phase 3 randomised FREEDOM trial and open-label extension.

Authors:  Henry G Bone; Rachel B Wagman; Maria L Brandi; Jacques P Brown; Roland Chapurlat; Steven R Cummings; Edward Czerwiński; Astrid Fahrleitner-Pammer; David L Kendler; Kurt Lippuner; Jean-Yves Reginster; Christian Roux; Jorge Malouf; Michelle N Bradley; Nadia S Daizadeh; Andrea Wang; Paula Dakin; Nicola Pannacciulli; David W Dempster; Socrates Papapoulos
Journal:  Lancet Diabetes Endocrinol       Date:  2017-05-22       Impact factor: 32.069

9.  Romosozumab or Alendronate for Fracture Prevention in Women with Osteoporosis.

Authors:  Kenneth G Saag; Jeffrey Petersen; Maria Luisa Brandi; Andrew C Karaplis; Mattias Lorentzon; Thierry Thomas; Judy Maddox; Michelle Fan; Paul D Meisner; Andreas Grauer
Journal:  N Engl J Med       Date:  2017-09-11       Impact factor: 91.245

Review 10.  Bisphosphonates for cardiovascular risk reduction: A systematic review and meta-analysis.

Authors:  Guido Kranenburg; Jonas W Bartstra; Maaike Weijmans; Pim A de Jong; Willem P Mali; Harald J Verhaar; Frank L J Visseren; Wilko Spiering
Journal:  Atherosclerosis       Date:  2016-06-24       Impact factor: 5.162
  10 in total
  4 in total

1.  Sclerostin inhibition alleviates breast cancer-induced bone metastases and muscle weakness.

Authors:  Eric Hesse; Saskia Schröder; Diana Brandt; Jenny Pamperin; Hiroaki Saito; Hanna Taipaleenmäki
Journal:  JCI Insight       Date:  2019-04-09

Review 2.  Targeting the Wnt signaling pathway for breast cancer bone metastasis therapy.

Authors:  Jingyao Cui; Haoran Chen; Kaiwen Zhang; Xin Li
Journal:  J Mol Med (Berl)       Date:  2021-11-25       Impact factor: 4.599

Review 3.  Skeletal changes during and after spaceflight.

Authors:  Laurence Vico; Alan Hargens
Journal:  Nat Rev Rheumatol       Date:  2018-03-21       Impact factor: 20.543

4.  MicroRNA-92b-5p modulates melatonin-mediated osteogenic differentiation of bone marrow mesenchymal stem cells by targeting ICAM-1.

Authors:  Yuan Li; Chao Feng; Manqi Gao; Mengyu Jin; Tianyi Liu; Ye Yuan; Gege Yan; Rui Gong; Yi Sun; Mingyu He; Yutuo Fu; Lai Zhang; Qi Huang; Fengzhi Ding; Wenya Ma; Zhenggang Bi; Chaoqian Xu; Natalia Sukhareva; Djibril Bamba; Russel Reiters; Fan Yang; Benzhi Cai; Lei Yang
Journal:  J Cell Mol Med       Date:  2019-07-14       Impact factor: 5.310
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.